Granite Point Capital Management’s Pacira BioSciences PCRX Stock Holding History

Granite Point Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-4,000	Closed	-$355K	–	109
2015 Q1	$355K	Sell	4,000 -5,000	-56%	-$507K	0.13%	87
2014 Q4	$798K	Sell	9,000 -1,000	-10%	-$94.6K	0.37%	49
2014 Q3	$969K	Hold	10,000	–	–	0.48%	44
2014 Q2	$919K	Sell	10,000 -2,400	-19%	-$183K	0.63%	35
2014 Q1	$868K	Buy	+12,400	New	+$843K	0.62%	52

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Granite Point Capital Management's PCRX Position: Q2 2015 in Review

Granite Point Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2015, closing a stake of 4,000 shares — an estimated $355K sold.

Granite Point Capital Management first reported a position in PCRX in Q1 2014 and held it in 5 quarters. The position peaked at $969K in Q3 2014. 187 funds tracked by Wall St. Rank hold PCRX as of Q2 2015.

Granite Point Capital Management reported no remaining Pacira BioSciences position as of Q2 2015 after selling out during the quarter.
Granite Point Capital Management sold 4,000 Pacira BioSciences shares in Q2 2015, an estimated $355K.
Granite Point Capital Management first reported a position in Pacira BioSciences in Q1 2014 and held it in 5 quarters.
Granite Point Capital Management's Pacira BioSciences position peaked at $969K in Q3 2014.
187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2015.

Based on Granite Point Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.